Displaying drugs 14851 - 14875 of 15206 in total
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
6-Methylamino-5-Nitroisocytosine
Experimental
Apratastat
Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).
Investigational
Alphamethadol
Experimental
Illicit
4-Flourobenzenesulfonamide
Experimental
AL5424
Experimental
3-Amino-4-Oxybenzyl-2-Butanone
Experimental
Phenylacetaldehyde
Experimental
AL7089A
Experimental
Benzylamine
Experimental
4-(Hydroxymethyl)Benzamidine
Experimental
1,3-Dinitrobenzene
Experimental
Para-Bromobenzyl Alcohol
Experimental
DAS869
Experimental
4-Fluorobenzylamine
Experimental
2,6-Difluorobenzenesulfonamide
Experimental
1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea
Experimental
3-Iodo-Benzyl Alcohol
Experimental
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol
Experimental
4-(trifluoromethyl)phenol
Experimental
Displaying drugs 14851 - 14875 of 15206 in total